Asunto(s)
Ideación Suicida , Suicidio , Humanos , Medición de Riesgo , Factores de Riesgo , Intento de SuicidioRESUMEN
OBJECTIVE: Suicide prevention certainly includes a better knowledge of suicide risk in primary care. A number of international publications have shown interest in assessing this risk, but mostly through specific consultant populations: young patients, old patients, anhedonic, depressive, etc. Our study analyses suicide risk prevalence in patients consulting in general medicine for any somatic or psychiatric reason, their pathology or their age. METHOD: This cross-sectional study was conducted with adult patients (827 subjects included) who were consulting a French generalist doctor panel randomly selected. They filled a validated self-questionnaire (aRSD) assessing their suicide risk in the 15 preceding days and providing professional and personal data. RESULTS: The totally operable 757 files (483 female; 274 male) show that close to a quarter of consultants (24.3%) presents with a positive suicide risk in the 15 days preceding their consultation and 6.3%, reveal a severe risk (aRSD ≥ 7) with ideas and impulses to commit the act. When the reason to consult is psychiatric, 64.6% of these consultants have aRSD positive. One time out of two, the risk is even severe. CONCLUSIONS: This data shows how important the suicide risk prevalence is in general medicine. It confirms the main role played by primary care patricians in acting to prevent suicide risk. This data also shows the contribution represented by a self-questionnaire that would rapidly assess the suicide intent while screening, it.
Asunto(s)
Ideación Suicida , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , Encuestas y CuestionariosAsunto(s)
Accidentes de Aviación/psicología , Suicidio/psicología , Autopsia , Alemania , Humanos , Pilotos/psicología , PsiquiatríaRESUMEN
Suicide prevention represents a major challenge to public health, and the suicide risk is a permanent concern in psychiatry. But the main difficulty is its diagnosis. What resources are available in French which seem to help therapists in this process? We can distinguish the non-dimensional approach, the use of self-administered questionnaires or interviewer-administrated questionnaires. In this paper, for reasons of editing constraints, we are interested only in a non-dimensional approach and direct assessment measures by self-assessment, analysing the strengths and limitations of each and taking into account scientific studies that have been devoted to them and their clinical relevance. We first considered various aspects of non-dimensional approach through suicidal risk factors research, suicidal emergency and suicidal potential concepts, Shea approach, the model of Mann and some recommended evaluations. This type of approach has a number of advantages, but also limitations. Dimensional approach allows going further. In this article, we also discuss the existing self-assessment tools in French as for example dedicated item for Beck Depression Inventory (BDI) or specific scales such as Reasons for Living Inventory (RFL), Suicidal Probability Scale (SPS), Beck Hopelessness Scale (BHS) and self-administered Suicide Risk Assessment Scale of Ducher (aRSD). These last two seem to be used as a priority regarding result of their validation studies. The strong correlation between the self-administered questionnaire aRSD and the interviewer-administered Suicide Risk Assessment Scale of Ducher RSD (r=0.92; P<10(-7)) shows the ability of patients to express their suicidal ideation if we want to invite them to do so.
Asunto(s)
Autoevaluación (Psicología) , Prevención del Suicidio , Suicidio/psicología , Francia , Humanos , Escalas de Valoración Psiquiátrica , Medición de Riesgo , Ideación Suicida , Intento de SuicidioAsunto(s)
Suicidio/tendencias , Comparación Transcultural , Estudios Transversales , Francia , Humanos , Incidencia , Psicometría/estadística & datos numéricos , Reproducibilidad de los Resultados , Medición de Riesgo/legislación & jurisprudencia , Medición de Riesgo/tendencias , Suicidio/legislación & jurisprudencia , Suicidio Asistido/legislación & jurisprudencia , Suicidio Asistido/prevención & control , Suicidio Asistido/tendencias , Intento de Suicidio/legislación & jurisprudencia , Intento de Suicidio/prevención & control , Intento de Suicidio/tendencias , Encuestas y Cuestionarios , Prevención del SuicidioRESUMEN
INTRODUCTION: Most of the people who will attempt suicide, talk about it beforehand. Therefore, recognition of suicidal risk is not absolutely impossible. Beck's suicidal ideation scale and Ducher's suicidal risk assessment scale (RSD) are common tools to help practicians in this way. AIM OF THE STUDY: These scales and the Hamilton's depression scale were included in an international multicentric, phase IV, double-blind study, according to two parallel groups who had been administered a fixed dose of fluvoxamin or fluoxetin for six weeks. This allowed examination of the correlations between these scales and the relations, which could possibly exist between suicidal risk, depression and anxiety. RESULTS: (a) Relationships between the Beck's suicidal ideation scale, the suicidal risk assessment scale RSD and Hamilton's depression before treatment. Before treatment, the analysis was conducted with 108 male and female depressive outpatients, aged 18 or over. Results revealed a significant positive correlation (with a Pearson's correlation coefficient r equal to 0.69 and risk p<0.0001) between Beck's suicidal ideation scale and the suicidal risk assessment scale RSD. These scales correlate less consistently with Hamilton's depression (Beck/Hamilton's depression: r=0.34; p=0.0004-RSD/Hamilton's depression: r=0.35; p=0.0002). We observed that the clinical anxiety scale by Snaith is also strongly correlated to these two suicidal risk assessment scales (Beck/CAS: r=0.48; p<0.0001-RSD/CAS: r=0.35; p=0.0005). Besides, the item "suicide" of Hamilton's depression scale accounts for more than a third of the variability of Beck's suicidal ideation scale and the suicidal risk assessment scale RSD. According to these results, the suicidal risk evaluated by these two scales seems to be significantly correlated with anxiety as much as with depression. On the other hand, the Clinical Global Impression is fairly significantly correlated with Beck's suicidal ideation scale (r=0.22; p=0.02), unlike the suicidal risk assessment scale RSD (r=0.42; p<0.0001) and Hamilton's depression scale (r=0.58; p<0.0001); (b) Relationships between Beck's suicidal ideation scale, the suicidal risk assessment scale RSD and Hamilton's depression under treatment. The follow-up under treatment (fluvoxamin or fluoxetin) during six weeks revealed the significantly better sensitivity of the RSD in comparison with Beck's suicidal ideation scale and Hamilton's depression scale, showing the significantly faster improvement in the RSD (p<0.0001). There was no significant difference between the evolution of Beck's suicidal ideation scale and Hamilton's depression scale. So, under treatment with fluvoxamin or fluoxetin, the improvement in suicidal risk appears to be as rapid as the improvement in depression. If we look at the treatment prescribed, only the suicidal risk assessment scale RSD revealed a significant difference between the two molecules, with more rapid improvement with fluvoxamin (p=0.015) from D14. CONCLUSION: In conclusion, the results of this study hypothesize that the suicidal risk, as assessed by Beck's suicidal ideation scale and the suicidal risk assessment scale RSD, appears to be consistently correlated with both the level of anxiety and depression. The study also suggests that all antidepressants may not be equally effective on suicidal risk.
Asunto(s)
Trastorno Depresivo Mayor/diagnóstico , Escalas de Valoración Psiquiátrica , Intento de Suicidio/psicología , Adulto , Trastorno Depresivo Mayor/epidemiología , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Masculino , Medición de Riesgo , Índice de Severidad de la Enfermedad , Intento de Suicidio/estadística & datos numéricosRESUMEN
INTRODUCTION: A part (60% to 70%) of those who are going to act out their suicide consult a doctor the month before. Studies have shown the need to improve the practitioner's capacity to diagnose depression. The assessment of the suicidal risk is crucial. The search for suicidal risk factors helps to define the populations at risk. However, it doesn't provide information concerning the possibility of acting out in the short term. And how does one react when faced with those who do not present any of the risk factors? Psychometric instruments attempt to help the therapist in his/her reasoning. SUICIDAL RISK ASSESSMENT: Among them, the suicidal risk assessment scale RSD should be mentioned. Its objective is to estimate the seriousness of the suicidal risk, with 11 levels. It is built around a possible will to commit suicide rather than a single assessment of the frequency of suicidal ideas. Its construction in hierarchical order permits the progressive assessment of the suicidal risk, in the form of a semi-structured interview. Hence, the suicidal risk assessment scale RSD looks for the existence of death wishes (levels 1-2), of suicide ideations and its frequency (levels 3-4-5), and of a passive desire to die (level 6). Level 7 shows the onset of a decision making process, except that the patient is still inhibited by various important factors in his/her life. More often, the fear of inflicting immense suffering to his/her loved ones or for religious beliefs, is found. From level 8, determination has made way to hesitation. An active death wish exists, and although the plan remains undefined, the act is decided on. At level 9 the methods of application are developed and a plan is established. The ultimate level exists when there is a start in the preparation of the act of suicide (level 10). This hierarchical order has been confirmed by some epidemiological studies. METHOD: The inclusion of the suicidal risk assessment scale RSD in a double-blind, placebo-controlled study, which tested the efficacy of fluvoxamine in reducing the risk of recurrence of depression over 18 months, appears of particular interest. In this multicentre study, patients of both sexes were included, aged between 18 and 70 years, presenting a major depressive episode with a MADRS equal to a minimum of 25, and having had a minimum of two episodes of major depression within the last five years. RESULTS: The resulting analysis carried out on 103 patients showed a satisfactory concurrent validity between the suicidal risk assessment scale RSD and the items "suicide" of the MADRS (rho=0.79; p=0.0001) and the Hamilton Depression Scale (rho=0.70; p=0.0001), and fairly satisfactory concurrent validity with the depression degree assessed by the MADRS overall score (rho=0.40; p=0.0001). The short-term follow-up under treatment revealed enhanced sensitivity of the RSD versus the MADRS. The improvement in suicidal risk, assessed by the RSD, was faster than the improvement in depression, which is interesting from a clinical point of view. The medium-term follow-up tested the predictive validity of RSD and confirmed a greater level of suicidal risk from a score of 7 on the RSD, with the death by suicide of 2 subjects among the 15 who exhibited a score between 7 and 10 on the RSD on inclusion. On the other hand, no acting out, no attempted suicides, and no suicides were noted in the group of 88 subjects whose RSD was lower or equal to 6 on inclusion (p=0.02 using Fisher's exact test). CONCLUSION: Thus, the RSD appears of interest, from a clinical point of view, by providing a -diagnostic, or a scientific approach.
Asunto(s)
Antidepresivos de Segunda Generación/uso terapéutico , Trastorno Depresivo Mayor/psicología , Fluvoxamina/uso terapéutico , Entrevista Psicológica , Determinación de la Personalidad/estadística & datos numéricos , Medición de Riesgo/estadística & datos numéricos , Ideación Suicida , Prevención del Suicidio , Suicidio/psicología , Adulto , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/tratamiento farmacológico , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Inventario de Personalidad/estadística & datos numéricos , Psicometría/estadística & datos numéricos , Reproducibilidad de los Resultados , Prevención SecundariaRESUMEN
The prevention of suicide is a top priority in mental health. The determination of high risk suicidal groups is not sufficient. The expressing suicidal ideas is not a protective factor, but in contrary a risk factor to take into account, or even to search and to quantify: 80% of the subjects who attempt to commit suicide or commit suicide express such ideas months before. Several evaluation instruments try to help the practitioners or the research workers in this reasoning. The suicidal risk assessment scale RSD can be cited in particular. It is composed of eleven sections. The 0 level corresponds to the absence of particular ideas of death or suicide. Levels 1 and 2, the presence of ideas of death. Levels 3-4-5, the presence of suicidal ideas. The difference compared to the majority of the other scales consecrated to the same subject, the passif desire of death, occupies a place totally particular in the RSD (level 6). From the level 7, the risk of acting out seems to become more important. It stops being a simple idea of suicide, but becomes a real will of dying, firstly retained by something or someone (level 7), the fear of causing suffering to dear ones or a religious belief., then determined (level 8). Finally, the patient has elaborated a concrete plan (level 9) or he has already started the preparation of acting out (level 10). It is just necessary to evaluate and to note the highest level of the scale. The inclusion of the suicidal risk assessment scale RSD and of the Suicidal Ideation Scale by Beck in an international multicenters, phase IV, double-blind study, according to two parallel groups, with a fixed dose of fluoxétine or fluvoxamine for six weeks, allowed to search correlations which could exist between the two scales. The ana-lysis before the beginning of the treatment was done on 108 outpatients depressive, male and female, aged 18 or over. It finds a satisfactory concurrent validity between the suicidal risk assessment scale RSD and the Suicidal Ideation Scale by Beck (r=0.69; p<0.0001) as well as between the RSD and the item "suicide" of the Depression scale by Hamilton (r=0.60; p<0.0001). On the other hand, it is less satisfactory between the suicidal risk assessment scale RSD and the Hamilton Depression scale overall score (r=0.35; p=0.0002). During the evolution under the treatment, the suicidal risk assessment scale RSD shows an improvement significantly faster than the Hamilton Depression scale or the Beck's Suicidal Ideation Scale (p<0.0001). This statement of fact arouses some questions about the suicidal risk of which the evolution in the case of a treated depressive episode could be quicker than first thought. All the more so as this difference is affected by the type of the treatment (p=0.015). Moreover, a score of 7 and more on the suicidal risk assessment scale RSD seems to represent a risk level judged particularly significant by the experimenters. In effect, the existence of such a suicidal risk was a criteria of exclusion and no patient with a level superior to 6 on suicidal risk assessment scale RSD was included. In conclusion, the utilisation of the suicidal risk assessment scale RSD could be interesting in the prevention of suicide.
Asunto(s)
Depresión/epidemiología , Medición de Riesgo , Suicidio/estadística & datos numéricos , Encuestas y Cuestionarios , Adolescente , Adulto , Anciano , Depresión/tratamiento farmacológico , Método Doble Ciego , Femenino , Fluoxetina/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , SerotoninaRESUMEN
The effects of five beta blockers on the central nervous system of healthy subjects was studied by computerized EEG analysis. All subjects underwent continuous recording with a Holter magnetic type recorder during the experimental period. For 10 consecutive days, five groups of subjects received alternately placebo and the beta blockers acebutolol 600 mg, carteolol 20 mg, metoprolol 200 mg, pindolol 30 mg and sotalol 320 mg. EEG recordings (C4/P4, P4/02 and C3/P3, P3/01) lasting 5 min were made between 8.30 and 9.30 a.m. Subjects were at rest with eyes closed and there was no vigilance control. The signal was recorded on a magnetic tape recorder and then processed by Nicolet MED 80 system. Comparisons of absolute and relative powers and of average frequencies were then made between the different sequences and groups. The possible correlations between the changes observed in the power spectrum and the clinical, pharmacological and pharmacokinetic specific properties of each beta blocker are discussed.